glioma in Medical Technology

Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate

... to initiate a Phase III clinical study in glioma in the second half of 2008. BPH is a common ... completed a Phase II clinical trial of Litx in glioma and plans to initiate a Phase III trial in glioma during the second half of 2008. LSO has widened ...

Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting

... Board #J13; GU General Poster Session, May 31, 2:00 p.m.-6:00 p.m. glioma Fiveash J, et al. NABT-0702: A phase II study of AT-101 in recurrent ... malignancies (with Rituxan(R)), small cell lung cancer (with Hycamtin(R)), glioma (with Temodar(R), +/- chemoradiotherapy [XRT]) and esophageal cancer (with ...

Light Sciences Oncology Raises $40.1 Million in Series C Financing

... the liver, the company has completed a Phase II clinical trial of Litx in glioma and plans to initiate a Phase III trial in glioma during the second half of 2008. LSO has widened the scope of potential ...

St. Jude Finds Young Age May Give Survival Advantage to Children With Certain Brain Tumors

... The improved survival of children under 3 years old with diffuse pontine glioma compared to older children suggests that the biological properties of this ... children under 3 years old who have a brain tumor called diffuse pontine glioma (DPG) appear to have a better outcome than older children with the same ...

Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting

... Wafer is indicated in patients with newly diagnosed high-grade malignant glioma as an adjunct to surgery and radiation. Gliadel is also indicated in ... of the components of Gliadel. Patients undergoing craniotomy for malignant glioma and implantation of Gliadel should be monitored closely for complications ...

Cancer Research 'David' Hopes to Slay 'Cancer Goliath'

... lung, spine, pancreas, prostate, ovary, and stomach. In addition, some effectiveness was seen in an instance of lymphoid leukemia, and one of a glioma of the ocular nerve. These tests preceded his more recent death due to an unfortunate accident. As a small Foundation hard hit by the untimely ...

Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer

... lung cancer (with Taxotere(R) [docetaxel]), B-cell malignancies (with Rituxan(R) [rituximab]), small cell lung cancer (with Hycamtin(R) [topotecan]), glioma (with Temodar(R) [temozolomide], +/- chemoradiotherapy [XRT]) and in esophageal cancer (with docetaxel, 5-fluorouracil and XRT). Recently, two ...

YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia

... in several randomized Phase II and III trials in Japan, Europe and elsewhere and is undergoing a YM-sponsored confirmatory trial in pediatric glioma in Canada and the US. NYSE Alternext US notice The Company received an audit opinion for the fiscal year ended June 30, 2008 which ...

Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months

... vaccine containing a peptide from Tyrosinase-Related Protein 2 (TRP-2), an antigen commonly expressed by several types of tumors including glioma and melanoma, resulted in approximately a 100-fold increase in antigen-specific CD8+ T-cell responses compared with unformulated vaccine. CD8+ ...

Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials

... A recent article published in Neuro-Oncology (Lamborn et al, 2008) examined six-month progression free survival as a predictor of overall survival in glioma patients. The article included data from 597 adult patients with recurrent high-grade gliomas that enrolled in Phase II trial protocols collected by ...

Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements

... rate was accepted as the endpoint for conditional approval. The drug designed for the targeted treatment of recurrent or refractory high-grade glioma was administered as monotherapy and compared to standard chemotherapy in an international, randomized, active-controlled Phase IIb clinical trial. ...

Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma

... is currently being planned. "The results of the Phase I/II study underscore again the high efficacy of AP 12009, which we have seen in high-grade glioma patients in the active-controlled Phase IIb study AP12009-G004. This study showed a strong survival benefit in patients treated with AP 12009 ...

Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting

... in the United States. Glioblastoma multiforme (GBM), a type of glioma, is rapidly progressive and nearly uniformly lethal. Currently, malignant glioma is managed through a combination of chemotherapy, surgery and radiation. With modern combination therapy, the mean duration of survival has increased ...

BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer

... the expansion of the clinical program for the company's lead product candidate, BSI-201, into glioblastoma multiforme (GBM), the most common glioma in adults. BSI-201, the first poly ADP-ribose polymerase (PARP) inhibitor in BiPar's DNA repair portfolio, crosses the blood-brain barrier, a unique ...

Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine in Glioma Presented at American Association of Neurological Surgeons Annual Meeting

... Oncophage(R) (vitespen) in recurrent, high-grade glioma at the 75th annual meeting of the American ... goal is to change the management of recurrent glioma from a life threatening disease, in which ... impact." About Brain and Spinal Cord Tumors glioma is a cancer affecting the central nervous system ...

Data Presented at AACR Meeting Show Peregrine's Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer

... researchers injected rats with irradiated glioma cells (inactivated tumor cells) along with 2aG4. ... data are particularly noteworthy because the glioma cells used in the study are highly aggressive -- ... of 2aG4 and irradiated tumor cells to the glioma cell-challenged animals resulted in a robust ...

Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma

... on AP 12009 in the lead indication high-grade glioma as presented at this years ASCO Annual Meeting ... clinical development of AP 12009 in high-grade glioma and in other solid tumors.” The American ... 12009 (3, 4). General Background on High-Grade glioma Anaplastic astrocytoma and glioblastoma are the ...

2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion

... announced, that data from the Phase IIb-study with AP 12009 in high-grade glioma will be presented at the 43rd Annual Meeting of the American Society ... - is in advanced clinical development for the treatment of high-grade glioma as well as in Phase I/II clinical trial for the treatment of colorectal ...

Biomira Selects PX-866 as Clinical Development Candidate and Presents Promising Preclinical Data at AACR

... of Texas M. D. Anderson Cancer Center (MDACC) (Abstract #278) showed that PX-866 treatment resulted in growth inhibition in three different glioma cell lines. The magnitude of the inhibition depended on the status of PTEN in the cell lines, with PTEN-negative cells showing greater sensitivity to ...

Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study

... Research and Development Agreement (CRADA) with Merck KGaA for the development of cilengitide. An initial Phase I/II study in adult high-grade glioma (including glioblastoma) patients showed encouraging results.(5) Seven NCI-sponsored studies with cilengitide monotherapy in various tumor types, ...

MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting

... a biodegradable wafer containing the chemotherapy agent carmustine, or BCNU, and is indicated in newly diagnosed patients with high-grade malignant glioma as an adjunct to surgery and radiation. Gliadel is also indicated in recurrent glioblastoma multiforme patients as an adjunct to surgery. As a ...

MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting

... a biodegradable wafer containing the chemotherapy agent carmustine, or BCNU, and is indicated in newly diagnosed patients with high-grade malignant glioma as an adjunct to surgery and radiation. Gliadel is also indicated in recurrent glioblastoma multiforme patients as an adjunct to surgery. As a ...